Back to module
Evidence summary

Menopausal Hormone Therapy: Reading WHI Properly

Meridian · Women's Health After 50Generated: 4 August 2026

03Menopausal Hormone Therapy: Reading WHI Properly

Two decades of over-correction — what the trial actually showed, by age, by arm, and in absolute numbers.

Key takeaways

  • —The CEE-alone arm (hysterectomised women) showed a non-significant reduction in breast cancer incidence — the opposite of the public perception.
  • —Excess breast cancer with combined therapy is on the order of fewer than 1 extra case per 1000 women per year — comparable to two units of alcohol daily or obesity.
  • —In women aged 50–59 starting therapy within 10 years of menopause, coronary and mortality signals are neutral to favourable.
  • —WHI's average participant was 63 with a BMI of 28 — she is not the 52-year-old in your consulting room.
  • —No increase in all-cause mortality was seen in either arm over 18 years of cumulative follow-up (Manson, JAMA 2017).

Graded claims

A

Systemic MHT is the most effective treatment for moderate-severe VMS

Established — RCT / guideline-gradeConsistent RCT evidence; 75–90% reduction in frequency.

A

CEE-alone in hysterectomised women did not increase breast cancer incidence in WHI

Established — RCT / guideline-gradeNon-significant reduction sustained in long-term follow-up.

A

Combined MHT increases breast cancer incidence with duration of use

Established — RCT / guideline-gradeSmall absolute excess; risk attenuates after cessation.

B

Transdermal estradiol carries lower VTE risk than oral

Supported in defined populationsLarge observational and nested case-control evidence; no dedicated RCT.

C

MHT started in women aged 50–59 reduces all-cause mortality

Promising but preliminarySuggestive pooled and subgroup data; not a primary endpoint finding.

F

MHT should be prescribed to prevent dementia

Refuted or actively misleadingWHIMS showed increased dementia risk with late initiation; prevention is not an indication.

Supporting references

  1. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality (WHI 18-year follow-up) — Manson et al., JAMA 2017 https://pubmed.ncbi.nlm.nih.gov/28898378/
  2. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE) — Hodis et al., NEJM 2016 https://pubmed.ncbi.nlm.nih.gov/27028912/
  3. The 2022 Hormone Therapy Position Statement of The North American Menopause Society — Menopause 2022 https://pubmed.ncbi.nlm.nih.gov/35797481/
Educational summary for registered health professionals. Grades reflect strength of evidence at the time of writing and do not replace current national guidance, product licences or clinical judgement.